Review
Clinical Neurology
Thomas Williams, Henrik Zetterberg, Jeremy Chataway
Summary: Neurofilament light is consistently associated with current inflammatory activity and future brain atrophy in progressive multiple sclerosis, and is consistently shown to be a marker of treatment response with immunosuppressive disease-modifying therapies. On the other hand, neurofilament heavy evidence is more limited and inconsistent.,UnityEngineNeither neurofilament light nor heavy has shown a consistent treatment response to neuroprotective disease-modifying therapies.
JOURNAL OF NEUROLOGY
(2021)
Review
Neurosciences
Carolina Ferreira-Atuesta, Saul Reyes, Gavin Giovanonni, Sharmilee Gnanapavan
Summary: Multiple sclerosis (MS) is an autoimmune, inflammatory neurodegenerative disease characterized by demyelination and axonal damage. Neurofilament Light chain (NfL) has been identified as a biomarker of disease activity in MS, reflecting the extent of neuroaxonal damage and guiding treatment decisions.
FRONTIERS IN NEUROSCIENCE
(2021)
Article
Clinical Neurology
Dejan Jakimovski, Brianna L. Gibney, Karen Marr, Deepa P. Ramasamy, Michael G. Dwyer, Niels Bergsland, Bianca Weinstock-Guttman, Murali Ramanathan, Robert Zivadinov
Summary: The study found a negative correlation between cerebral arterial blood flow and serum neurofilament light chain levels in patients with multiple sclerosis, highlighting the relationship between cerebral hypoperfusion and axonal pathology.
EUROPEAN JOURNAL OF NEUROLOGY
(2022)
Article
Immunology
Igal Rosenstein, Sofia Rasch, Markus Axelsson, Lenka Novakova, Kaj Blennow, Henrik Zetterberg, Jan Lycke
Summary: This study suggests that determination of intrathecal immunoglobulin M synthesis (ITMS) and neurofilament light concentration in cerebrospinal fluid (CSF) can be useful biomarkers for predicting disease severity and disability in relapsing-remitting multiple sclerosis (RRMS). The combination of ITMS with CSF neurofilament light (cNfL) shows a stronger predictive value.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Clinical Neurology
Stefan Bittner, Jiwon Oh, Eva Kubala Havrdova, Mar Tintore, Frauke Zipp
Summary: Blood-based serum neurofilament light chain (sNfL) is being investigated as a biomarker for prognosis and treatment response in multiple sclerosis patients. It reflects ongoing inflammatory-driven neuroaxonal damage and has the potential to guide individualized clinical decision-making.
Article
Cell Biology
Hongge Wang, Matthew D. Davison, Martin L. Kramer, Weiliang Qiu, Tatiana Gladysheva, Ruby M. S. Chiang, Can Kayatekin, David R. Nascene, Leyla A. Taghizadeh, Carina J. King, Erin E. Nolan, Ashish O. Gupta, Paul J. Orchard, Troy C. Lund
Summary: Cerebral adrenoleukodystrophy (CALD) is a devastating neuroinflammatory manifestation, and finding biomarkers for this disease burden has been a long-standing goal. This study suggests that plasma neurofilament light chain (NfL) could be an important indicator in evaluating CALD outcomes, with a significant correlation to cerebral spinal fluid levels and a potential for decrease after therapeutic intervention.
Article
Medicine, General & Internal
Harald Hegen, Klaus Berek, Gabriel Bsteh, Michael Auer, Patrick Altmann, Franziska Di Pauli, Astrid Grams, Dejan Milosavljevic, Markus Ponleitner, Paulina Poskaite, Christine Schnabl, Sebastian Wurth, Anne Zinganell, Thomas Berger, Janette Walde, Florian Deisenhammer
Summary: This study aimed to investigate the additional predictive value of x-FLC index and sNfL Z score for MS disease activity. The results showed that both x-FLC index and sNfL Z score independently predicted the time to second clinical attack. The chance of relapse within 12 months was 2% for patients with high levels of x-FLC index (>100) and high sNfL Z score (>3), 30% for patients with high x-FLC index (>100) and lower sNfL Z score (<= 3), 70% for patients with lower x-FLC index (<= 100) but high sNfL Z score (>3), and 90% for patients with lower levels of x-FLC index (<= 100) and sNfL Z score (<= 3).
Review
Biochemistry & Molecular Biology
Jennifer Yang, Maysa Hamade, Qi Wu, Qin Wang, Robert Axtell, Shailendra Giri, Yang Mao-Draayer
Summary: Multiple sclerosis (MS) is a debilitating autoimmune disorder with a lack of effective treatment for the progressive form. Neurofilament light chain (NfL) has emerged as a potential biomarker for predicting MS disease activity and progression, but it is not specific to MS and can be influenced by age, BMI, and blood volume. Other biomarkers of axonal damage, neuronal damage, glial dysfunction, demyelination, and inflammation have also been studied, but they may face similar limitations as NfL. A comprehensive panel including cellular studies, miRNAs, EVs, metabolomics, metabolites, and the microbiome could provide a more useful approach. Further research using advanced technology and statistical approaches is needed to identify novel and useful biomarkers for MS.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Neurosciences
Federico Verde, Markus Otto, Vincenzo Silani
Summary: ALS and FTD are currently incurable neurodegenerative diseases lacking specific neurochemical biomarkers, but NFL has shown considerable progress as a biomarker in both diseases, distinguishing them from mimic conditions and providing prognostic information.
FRONTIERS IN NEUROSCIENCE
(2021)
Review
Clinical Neurology
Simon Thebault, Gauruv Bose, Ronald Booth, Mark S. Freedman
Summary: This review highlights the potential role of serum neurofilament light chain (sNfL) as a promising blood-derived biomarker in the routine management of multiple sclerosis (MS) patients. Various studies have shown associations of sNfL levels with outcomes of interest, including inflammatory activity, progression, treatment response, and prediction/prognosis, supporting its potential as an objective, convenient, and cost-effective adjunct to clinical assessment. Future research is needed to further explore the limitations of sNfL and pave the way for other promising biomarkers for precision medicine in MS patients.
MULTIPLE SCLEROSIS JOURNAL
(2022)
Article
Clinical Neurology
Feiyue Mi, Yingchun Wang, Wenqiang Chai, Ya Chen, Xuhua Yin
Summary: This study compared the levels of plasma neurofilament light (NfL) in patients with multiple sclerosis (MS) at acute and remission stages and healthy individuals, and found that plasma NfL levels could be a potential biomarker for monitoring disease activity and severity, as well as predicting disease prognosis.
FRONTIERS IN NEUROLOGY
(2023)
Article
Clinical Neurology
Sarah Harris, Giancarlo Comi, Bruce A. C. Cree, Douglas L. Arnold, Lawrence Steinman, James K. Sheffield, Harry Southworth, Ludwig Kappos, Jeffrey A. Cohen
Summary: This study investigated plasma neurofilament light chain concentration (pNfL) as a biomarker for neuroaxonal damage and disease activity in relapsing multiple sclerosis (RMS). Results showed that pNfL was associated with clinical and radiologic measures of disease and treatment effects in RMS, supporting its use as a biomarker. Ozanimod treatment led to greater reduction in pNfL compared to interferon beta-1a, with decreased inflammatory activity and improved disease outcomes.
EUROPEAN JOURNAL OF NEUROLOGY
(2021)
Review
Biology
Ebrahim Kouchaki, Fatemeh Dashti, Seyed Mohammad Ali Mirazimi, Zahra Alirezaei, Seyed Hamed Jafari, Michael R. Hamblin, Hamed Mirzaei
Summary: The treatments for multiple sclerosis have improved over the years, but the main challenge now is determining the appropriate patients for treatment and its duration. There is a significant need for accurate laboratory measurements for diagnosis and monitoring of treatment response, with NfL emerging as a potential new biomarker to explore.
Article
Neurosciences
Assunta Ingannato, Silvia Bagnoli, Salvatore Mazzeo, Valentina Bessi, Sabrina Mata, Monica Del Mastio, Gemma Lombardi, Camilla Ferrari, Sandro Sorbi, Benedetta Nacmias
Summary: The study found that intermediate alleles and plasma NfL levels may potentially serve as biomarkers in ALS, with higher frequency of IAs in the patient cohort, increasing NfL levels with age at onset, and differences in NfL concentration and age at onset between bulbar and spinal onset groups.
FRONTIERS IN NEUROSCIENCE
(2021)
Article
Behavioral Sciences
Thomas Williams, Amanda Heslegrave, Henrik Zetterberg, Katherine A. Miszkiel, Frederik Barkhof, Olga Ciccarelli, Wallace J. Brownlee, Jeremy Chataway
Summary: This study found that persistently elevated blood neurofilament light (bNfL) levels may be more common in multiple sclerosis patients with a poor long-term outcome. This suggests that blood bNfL may serve as an additional prognostic biomarker, providing important information for personalized treatment.
BRAIN AND BEHAVIOR
(2022)
Article
Clinical Neurology
Zahra Ghadimi Korka, Shohreh Noorizadeh Dehkordi, Soheil Mansour Sohani, Marzieh Yassin
Summary: The Trunk Impairment Scale (TIS) in Persian has been found to be a relevant and reliable tool for assessing trunk abnormalities in Persian-speaking people with multiple sclerosis (PWMS).
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2024)
Letter
Clinical Neurology
Daniele Caliendo, Maria Carmela Grassia, Antonio Carotenuto, Maria Petracca, Roberta Lanzillo, Vincenzo Brescia Morra, Marcello Moccia
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2024)
Article
Clinical Neurology
Maddalena Sparaco, Elisabetta Maida, Floriana Bile, Renato Vele, Luigi Lavorgna, Giuseppina Miele, Simona Bonavita
Summary: The SDQ was translated into Italian and validated for use in pwMS to detect swallowing disturbances. The 14-item SDQ demonstrated high internal consistency, good accuracy, and reliability in pwMS, making it a readily applicable tool for investigating dysphagia in MS.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2024)
Article
Clinical Neurology
Leticia Rodrigues Gomes, Benito Pereira Damasceno, Brunno Machado de Campos, Alfredo Damasceno
Summary: This study found that patients with multiple sclerosis (MS) have more frequent work restrictions and impairment in money management and driving abilities compared to controls. Cognitive function, physical disability, and MS lesion burden are strongly associated with work restrictions, and social cognition can influence financial capacity. Cognitive and brain reserve can help retain some of these daily occupations.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2024)
Letter
Clinical Neurology
Kaitlin E. Riegler, John Beauvais, Lindsay O. Neto, Elizabeth S. Gromisch
Summary: This study examined the differences in resilience levels among individuals with multiple sclerosis (PwMS) who had sleep disorders, sleep problems, and no sleep disorders/problems. The results showed that PwMS with sleep disorders had significantly lower resilience, with the difference being driven by the support from family and friends. These findings highlight the connection between sleep and resilience in PwMS, emphasizing the importance of social support.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2024)
Article
Clinical Neurology
A. Maunula, S. Atula, Sm Laakso, Pj Tienari
Summary: This study aimed to investigate the frequency and risk factors of FTY rebound in a hospital district in Southern Finland. The results showed that 10.5% of patients experienced a rebound, and 28% of patients had relapses of any severity after discontinuing FTY. Younger age at diagnosis, longer exposure to FTY, lower lymphocyte count, and higher neutrophil to lymphocyte ratio after discontinuation were identified as risk factors for a rebound.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2024)